The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Share News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: 0.00 (0.00%)
Spread: 0.25 (3.448%)
Open: 7.375
High: 7.375
Low: 7.375
Prev. Close: 7.375
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Woodbois rises as plots Mozambique exit

Wed, 13th Mar 2024 11:12

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Woodbois Ltd, up 7.6% at 0.78 pence, 12-month range 0.22p-1.30p. The maker of sustainable timber products says it will exit Mozambique, as it believes its operations there "have not and cannot contribute meaningfully" to profit. It will sell its operations in the southern African nation to a "local purchaser", after striking a letter of intent. "A comprehensive sale agreement is expected to be entered into in the coming weeks," it adds. Woodbois also notes "heightened geopolitical risks" are a cause for concern in the region, particularly in the northern Cabo Delgado province, which is grappling with a surge of violence from fighters part of the Islamic State group. Woodbois says some of its concessions are located in Cabo Delgado. "The ban on exports of local wood, have further contributed to this strategic decision," it adds.

----------

AIM - LOSERS

----------

Cap-XX Ltd, down 82% at 0.073p, 12-month range 0.060p-2.90p. The manufacturer of supercapacitors for portable electronic devices warns its "working capital position has continued to deteriorate". Revenue and cash receipts over the first eight weeks of the year have been weaker than expected. It is exploring raising additional financing but believes some sort of debt and sale/leaseback structures will not be possible. It is considering equity financing but cautions that this process is taking longer than expected. It is now in a "highly constrained financial position" and additional financing is needed by the end of this month.

----------

Ixico PLC, down 14% at 7.27p, 12-month range 6.35p-25.00p. The neuroscience focused advanced analytics company says its financial first half has been marred by "longer contracting cycles and postponements of certain new contracts to later in the year" or the next one. Ixico's financial year ends on September 30. Ixico says delays to some project start dates are likely to mean revenue for financial 2024 totals GBP5.2 million to GBP5.9 million. Revenue in the prior year amounted to GBP6.7 million. Chief Executive Giulio Cerroni adds: "Whilst anticipating a challenging first half year of trading, we had expected higher levels of new contract bookings, especially from biotech sponsors, which have not yet materialised, primarily due to client-led delays."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
18 Oct 2021 09:33

Ixico FY revenues projected to beat expectations

(Sharecast News) - AI data analytics company Ixico said on Monday that full-year revenues were projected to have beat expectations despite falling shy of prior year comparatives.

Read more
22 Sep 2021 11:19

Ixico secures new contract valued at more than $750,000

(Sharecast News) - AI data analytics firm Ixico has secured a new contract valued at more than $750,000 over two years for advanced neuroimaging solutions.

Read more
8 Sep 2021 12:47

Ixico awarded phase 1 clinical trial contract

(Sharecast News) - Neuroscience artificial intelligence (AI) company Ixico has been awarded a contract by a new biopharmaceutical client to support its phase 1 multiple system atrophy clinical trial, it announced on Wednesday.

Read more
6 Aug 2021 14:53

Ixico confident as full-year revenue, earnings decline

(Sharecast News) - Data analytics company Ixico updated the market on its trading on Friday, confirming that despite a "challenging" business environment, it expected to deliver £8.7m in revenues for the 2021 financial year.

Read more
26 Apr 2021 09:06

Ixico H1 revenues grow despite Covid-19 impacts on clinical development sector

(Sharecast News) - Clinical research firm Ixico said on Monday that revenues were expected to have improved in the six months ended 31 March, despite the impacts of the Covid-19 pandemic on the clinical development sector.

Read more
15 Mar 2021 10:13

Ixico strikes collaboration deal with Microsoft

(Sharecast News) - Data analytics company Ixico said on Monday that it had struck a collaboration agreement with tech giant Microsoft to develop its artificial intelligence analytics platform for the global pharmaceutical industry.

Read more
10 Mar 2021 14:30

Ixico selected for Alzheimer's clinical trial

(Sharecast News) - Neuroscience artificial intelligence (AI) analytics company Ixico has been selected by a current mid-sized biopharmaceutical client to support a phase 2 Alzheimer's disease clinical trial, it announced on Wednesday.

Read more
24 Dec 2020 12:20

Ixico awarded ?3.4m contract by existing client

(Sharecast News) - Artificial intelligence (AI) data analytics company Ixico has been awarded a £3.4m contract to run over 4.5 years by an existing client, it announced on Thursday, for a spinocerebellar ataxia type-3 (SCA3) trial.

Read more
8 Dec 2020 09:26

Ixico to provide neuroimaging solutions to unnamed global pharmaceutical group

(Sharecast News) - Data analytics firm Ixico has secured a contract for neuroimaging solutions with a "large global pharmaceutical company".

Read more
27 Nov 2020 12:09

Ixico executes contract for Huntington's disease clinical trial

(Sharecast News) - Neuroscience data analytics company Ixico has executed a contract to provide neuroimaging services that would support a phase 1b and 2 clinical trial for Huntington's disease, it announced on Friday.

Read more
3 Nov 2020 10:43

Ixico wins new contracts in Alzheimer's clinical trials

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Alzheimer's disease (AD) clinical trials, it announced on Tuesday.

Read more
22 Oct 2020 15:00

Ixico secures two Huntington's disease clinical trial contracts

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Huntington's disease clinical trials.

Read more
19 Oct 2020 09:38

Ixico FY revenues grow by more than a quarter

(Sharecast News) - AI data analytics company Ixico said on Monday that full-year revenues were up year-on-year as its data analytics service strategy continued to drive growth.

Read more
16 Oct 2020 16:23

Ixico enters deal with NUY Langone Health for drug trial

(Sharecast News) - Data analytics company Ixico has entered into an agreement with NYU Langone Health to support a trial to determine if the immunosuppressant drug Sirolimus, approved by the FDA to prevent organ transplant rejection and for the treatment of a rare and progressive lung disease called lymphangioleiomyomatosis, is also able to slow the progression of disease in people with multiple system atrophy (MSA).

Read more
24 Sep 2020 16:30

Ixico joins Friedreich's Ataxia research consortium

(Sharecast News) - Data analytics company Ixico has entered into a five-year collaboration with the Friedreich's Ataxia Research Alliance (FARA), it announced on Thursday, which it described as a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.